ARHGDIB Monoklonaler Antikörper

ARHGDIB Monoklonal Antikörper für IF-P

Wirt / Isotyp

Maus / IgG2b

Getestete Reaktivität

human

Anwendung

IF-P

Konjugation

CoraLite®594 Fluorescent Dye

CloneNo.

3E7B7

Kat-Nr. : CL594-66054

Synonyme

3E7B7, GDIA2, GDID4, Ly GDI, Ly-GDI

---

• 

  IF Staining of human tonsillitis using CL594-66054

  Immunofluorescent analysis of (4% PFA) fixed paraffin-embedded human tonsillitis tissue using CoraLite®594 ARHGDIB antibody (CL594-66054, Clone: 3E7B7 ) at dilution of 1:200. Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

---

Geprüfte Anwendungen

• Erfolgreiche Detektion in IF-P: humanes Tonsillitisgewebe

Empfohlene Verdünnung

• Immunfluoreszenz (IF)-P: IF-P : 1:50-1:500

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Produktinformation

CL594-66054 bindet in IF-P ARHGDIB und zeigt Reaktivität mit human

• Getestete Reaktivität: human
• Wirt / Isotyp: Maus / IgG2b
• Klonalität: Monoklonal
• Typ: Antikörper
• Immunogen: ARHGDIB fusion protein Ag9091
• Vollständiger Name: Rho GDP dissociation inhibitor (GDI) beta
• Berechnetes Molekulargewicht: 201 aa, 23 kDa
• Beobachtetes Molekulargewicht: 27 kDa
• GenBank-Zugangsnummer: BC009200
• Gene symbol: ARHGDIB
• Gene ID (NCBI): 397
• Konjugation: CoraLite®594 Fluorescent Dye
• Excitation/Emission maxima wavelengths: 588 nm / 604 nm
• Form: Liquid
• Reinigungsmethode: Protein-A-Reinigung
• Lagerungspuffer: PBS with 50% glycerol, 0.05% Proclin300, 0.5% BSA
• Lagerungsbedingungen: Bei -20°C lagern. Vor Licht schützen. Nach dem Versand ein Jahr stabil. Aliquotieren ist bei -20^oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

ARHGDIB, also known as RhoGDI2, is a conserved member of the RhoGDI family and plays an important role in cell migrations. It regulates the GDP/GTP exchange reaction of the Rho proteins by inhibiting the dissociation of GDP from them, and the subsequent binding of GTP to them. It is mainly in hematopoietic, endothelial, and epithelial cells. It has been linked to tumorigenesis and metastasis. RhoGDI2 expression is downregulated in several cancer types, such as bladder, lung and lymphoma, but is upregulated in prostate and gastric cancer.